CRISPR Therapeutics Reports Strong Q2 2026 Growth on CASGEVY Momentum
Event summary
- CASGEVY revenue hit $76M in Q2 2026, up 151% year-over-year.
- FDA approved CASGEVY for children as young as 2 years old with SCD or TDT.
- CRISPR Therapeutics initiated Phase 1 trials for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency).
- Cash position grew to $2.36B, up from $1.98B at year-end 2025.
The big picture
CRISPR Therapeutics is capitalizing on the commercial success of CASGEVY while aggressively expanding its pipeline. The company's ability to secure regulatory approvals and execute on clinical trials will be critical as it competes in the rapidly evolving gene therapy space. With a strong cash position, CRISPR Therapeutics is well-positioned to fund its ambitious development plans.
What we're watching
- Regulatory Momentum
- Whether the FDA's rapid approval of CASGEVY for younger patients will accelerate adoption and reimbursement in other markets.
- Pipeline Execution
- The pace at which CRISPR Therapeutics can advance its in vivo gene editing programs through Phase 1 trials.
- Commercialization Strategy
- How CRISPR Therapeutics and Vertex will expand CASGEVY's global reach, particularly in regions with high unmet need.
Related topics